Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy

Ke-Hung Tsui, Yu-Hsiang Lin, Cheng-Pang Hou, Horng-Heng Juang, Chien-Lun Chen, Phei-Lang Chang, IH Shao
  • Drug Design Development and Therapy, October 2014, Dove Medical Press
  • DOI: 10.2147/dddt.s72197

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication


The following have contributed to this page: Horng-Heng Juang and professor Ke-Hung Tsui